Clinical trials: Nephrogenic Systemic Fibrosis
Chronic Kidney Disease, Renal Insufficiency
Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)
This will be an international, multi-center, post-marketing surveillance study in patients with moderate renal insufficiency who are administered gadodiamide, Omniscan, during a MRI.
- Trial name
- NCT00908310
- Testing
- Omniscan
- Where
- United States
- Volunteers
- 213 people
- Sponsor
- GE Healthcare
Contrast Media
Primovist / Eovist in Renally Impaired Patients
Patients with moderate to severe renal impairment scheduled for a magnetic resonance imaging (MRI) scan and injection with a contrast agent, Primovist/Eovist, will be asked to participate.
- Trial name
- PERI (NCT00908596)
- Testing
- Gadoxetic acid disodium (Primovist, BAY86-4873)
- Where
- 47 sites in United States, Australia and 7 more
- Volunteers
- 357 people
- Sponsor
- Bayer
Nephrogenic Systemic Fibrosis
Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis
The purpose of this study is to determine the efficacy of imatinib mesylate in reducing cutaneous thickening and tethering in patients with nephrogenic systemic fibrosis (NSF).
- Trial name
- GENESYF (NCT00677092)
- Testing
- Imatinib mesylate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Massachusetts General Hospital
Fibrosis, Kidney Failure
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
Assess potential risk for NSF in subjects with renal impairment (moderate) post magnevist injection. Subjects will be screened within 48 hours of previously scheduled MRI, those meeting the enrollment criteria will be enrolled…
- Conditions
- Fibrosis, Kidney Failure, Renal Insufficiency
- Trial name
- NCT00744939
- Testing
- Gadopentetate dimeglumine (Magnevist, BAY86-4882)
- Where
- 26 sites in United States
- Volunteers
- 168 people
- Sponsor
- Bayer